A PHASE 1/2A PLACEBO-CONTROLLED DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ARO-MAPT-SC IN HEALTHY SUBJECTS AND SUBJECTS WITH EARLY ALZHEIMER’S DISEASE.

Registry ID

AROMAPT-SC-1001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

ARROWHEAD PHARMACEUTICALS, INC.

Start date

2026-06-11

Last update

2026-04-23

Conditions

• ALZHEIMER'S DISEASE

Related clinical trials

• PHASE 2/3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF EXV-802 AND EXV- 801 IN THE TREATMENT OF AGITATION IN PARTICIPANTS WITH ALZHEIMER’S DISEASE DEMENTIA
• A PHASE 1, RANDOMIZED, PLACEBO-CONTROLLED STUDY WITH A DOUBLE-BLIND PERIOD WITH OPEN-LABEL EXTENSION PERIOD TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRATHECALLY ADMINISTERED ALN- 5288 IN ADULT PATIENTS WITH ALZHEIMER¿S DISEASE
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF KARXT + KARX-EC FOR THE TREATMENT OF AGITATION ASSOCIATED WITH ALZHEIMER’S DISEASE (ADAGIO-1)
• A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF TRONTINEMAB IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER’S DISEASE (MCI TO MILD DEMENTIA DUE TO AD)
• A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF TRONTINEMAB IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER’S DISEASE (MCI TO MILD DEMENTIA DUE TO AD)
• A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, SINGLE ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7812653 FOLLOWING INTRATHECAL ADMINISTRATION IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER’S DISEASE

View on source registry